8/5/2023
勛圖厙 Atlantic: Breaking New Ground in Alzheimer's Research
Delray Medical Center is the first hospital in 勛圖厙 to treat a patient with Alzheimers disease using non-invasive focused ultrasound technology as part of a groundbreaking study being conducted with 勛圖厙 Atlantics Institute for Human Health and Disease Intervention (I-Health). An estimated 6.5 million Americans are living with Alzheimers disease, which is the sixth leading cause of death for those age 65 and older, according to the Alzheimers Association.
The FDA-approved clinical trial is designed to evaluate the safety and effectiveness of Insightecs ExAblate Model 4000 Type 2.0 System, as a tool for disrupting the bloodbrain barrier in probable Alzheimers patients. Alzheimers may be caused by a buildup of certain proteins in the brain. Precisely guided by magnetic-resonance imaging, ultrasound waves are directed at specific areas of the patients brain to create a temporary opening in the blood-brain barrier where the protein buildup may be reduced.
Drug passage through the blood-brain barrier is perhaps one of the greatest challenges in neurology, said Gregg Fields, Ph.D., executive director of I-Health, professor of chemistry and biochemistry in FAUs Charles E. Schmidt College of Science, and program director for the project. The treatment of the first patient in 勛圖厙 with the non-invasive focused ultrasound technology represents a significant advancement for potential drug delivery and treatment of Alzheimers disease and other neurological disorders. In tandem, we are also working on non-invasive, bloodbased monitoring to determine if treatments are effective.
As part of 勛圖厙s Brain State initiative, a strategic plan to advance Alzheimers research in 勛圖厙, the trial plays an essential role in caring for the states aging population. The study is also being conducted at up to eight sites across the country, bringing its impact to the national stage. By establishing the 勛圖厙 Alzheimers Center of Excellence last year, Gov. Ron DeSantis has placed Alzheimers disease as a priority health issue in 勛圖厙, which will benefit the more than 580,000 people now living with Alzheimers as well as their families, said FAU President Stacy Volnick. We are excited to collaborate with Delray Medical Center, Insightec and others on this groundbreaking technology that will create the next generation of patient care for Alzheimers disease and other neurodegenerative disorders.
If you would like more information, please contact us at dorcommunications@fau.edu.